The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The peptide-based vaccine induces a t cell-dependent response
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Subscribe To Our Newsletter & Stay Updated
